Psoralen / EMD Serono - LARVOL DELTA

PD12 Narrowband ultraviolet B and psoralen plus ultraviolet A phototherapy for mycosis fungoides: a 17-year retrospective cohort study in a university teaching hospital (2007-2024). (PubMed, Br J Dermatol) - "While younger age, male sex and higher cumulative dose correlated with improved outcomes, these associations were not statistically significant. Further studies with larger cohorts and longer follow-up are needed to refine treatment protocols and optimize patient outcome."

Clinical • Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

SG14 Homozygous pathogenic variant in transgradient palmoplantar keratoderma: causative, contributory or irrelevant? (PubMed, Br J Dermatol) - "He is currently managed on acitretin 25 mg once daily and psoralen plus ultraviolet A. Acitretin at 50 mg alone was effective but was discontinued due to side-effects. Previous treatment with secukinumab and adalimumab was not beneficial...However, 10% of individuals with European ancestry are heterozygous carriers of loss-of-function variants in the FLG gene. This high carrier frequency in the general population suggests that FLG may be only a contributing factor, and other variants or environmental factors are important in the manifestation of PPK, if FLG variants are found in so many unaffected individuals."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases • Vitiligo • FLG

HX22 Shining a light on dermatology. (PubMed, Br J Dermatol) - "This plant contains bergapten and methoxsalen, psoralen derivatives with photosensitizing properties...From its origins in heliotherapy to cutting-edge technologies, phototherapy's history reflects a profound and enduring quest to harness the healing power of light. This journey underscores its vital role in both the past and future of dermatology."

Journal • Review • Acne Vulgaris • Atopic Dermatitis • Dermatology • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • Skin Cancer • Tuberculosis • Vitiligo

P087 Not so mycosis fungoides. (PubMed, Br J Dermatol) - "Case 3 is a 75-year-old man with stage IVA2 MF who developed red, itchy patches in flexural folds during psoralen-ultraviolet A and pegylated interferon therapy...She had a diagnosis of nonerythrodermic SS and palmoplantar hyperkeratosis, and had a complete response in blood and a partial response in skin following mogamulizumab-methotrexate combination therapy...Treatment options for MF, such as topical corticosteroids, phototherapy and systemic therapies, can suppress the immune system, thereby raising the risk of fungal skin infections. Our case series highlights that fungal skin infections can mimic MF in patients with MF/SS and emphasizes the importance of considering a secondary diagnosis when reviewing and treating these patients, particularly if they present with a new atypical rash."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Identification of flavonoid-based small molecule inhibitors with dual-targeting capability against RdRp and Mpro of SARS-CoV-2. (PubMed, Bioorg Med Chem Lett) - "Based on this, our study identified two derivatives through pharmacophore alignment between flavonoid scaffolds and the main protease (Mpro) inhibitor 13b: a psoralen-derived lignan (Comp.1) and a novel isoflavone analog (Comp.2), with dual-targeting capability against SARS-CoV-2 RdRp and Mpro...Both compounds maintained inhibitory activity against the PF07321332-resistant L50F/E166V double mutant Mpro, with IC₅₀ fold-change values of 1.23 and 1.18, respectively, compared to an 8.62-fold reduction for PF07321332. However, ADMET evaluation indicated that although compounds met basic physicochemical criteria (including molecular weight, TPSA, and compliance with Lipinski's Rule of Five), they still presented critical toxicological liabilities, including high genotoxicity risk (Comp.1: 0.838 probability) and CYP3A4 inhibition (>0.97), necessitating extensive structural optimization. This study confirms that flavonoid derivatives represent promising starting points..."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Ultra-low frequency oral psoralen plus UVA (PUVA) keeps patients with early-stage mycosis fungoides in durable long-term remission (ISDS 2025) - "Our previous work suggests that PUVA therapy creates a suppressive microenvironment, increases type I interferons, and eliminates the inflammatory infiltrate that accompanies clonal malignant T cells in the skin of MF patients. Together, these effects deprive tumor cells of growth stimulation."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

QbD assisted formulation, optimization and characterization of psoralen phytosome prepared through thin film hydration method. (PubMed, Drug Dev Ind Pharm) - "Statistical analysis (ANOVA) showed that lecithin type and phospholipid:drug ratio significantly affected formulation performance (see Table X, ANOVA in Supplementary Table S1).ConclusionsSL-based phytosomes improve psoralen dermal delivery by enhancing entrapment, penetration, and providing sustained release. These findings support phytosomal encapsulation as a promising topical delivery strategy for psoralen; however, direct bioavailability and in vivo/ex vivo validation is required to confirm therapeutic efficacy in psoriasis."

Journal • Dermatology • Immunology • Inflammation • Psoriasis

Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases. (PubMed, Drug Deliv Transl Res) - "Conventional and modified liposomes, niosomes, transfersomes, ethosomes, invasomes, cerosomes, liposomal gels, and niosomal gels were developed, co-encapsulating synthetic and nature-derived substances such as adapalene, amphotericin B, benzoyl peroxide, bicalutamide, bupivacaine, buprenorphine, curcumin, ginger, glycyrrhetinic acid, metformin, methotrexate, microRNA-21, minoxidil, nicotinamide, Nigella sativa seed oil, pentamidine, psoralen, resveratrol, simvastatin, tocopherol acetate, tretinoin, and virgin coconut oil. By co-encapsulating active substances with distinct mechanisms of action, the developed nanosystems provide synergistic therapeutic effects, leading to reduced toxicity and enhanced bioavailability, potentially resulting in improved clinical outcomes, and presenting a promising alternative to conventional treatments. Through addressing clinical and regulatory framework aspects, these innovative therapies might one day transition from bench to market to..."

Journal • Review • Acne Vulgaris • Alopecia • Dermatology • Immunology • Infectious Disease • Psoriasis • Vitiligo • MIR21

Starting a Blood Bank inside a Private Practice (ASH 2024) - "Clinical Outcomes : Since September 1, 2023 to June 30, 2024, these capabilities have enabled us to administer 309 psoralen-treated pheresis platelet units, 115 packed red blood cell (pRBC) units, and 452 irradiated, pRBC units...Conclusions : We demonstrate that transfusions in non-hospital settings are safe and cost effective to meet a patient's transfusion needs. Changes in CMS billing regulations could make this practice widely available."

Cost-Effectiveness of Delgocitinib vs. PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream and psoralen with ultraviolet A (PUVA) light therapy are treatment options for patients with moderate or severe Chronic Hand Eczema (CHE) which has not adequately responded to treatment with topical corticosteroids...Efficacy and utility evidence for delgocitinib were derived from the DELTA 1, DELTA 2 clinical trials versus vehicle cream, and DELTA FORCE clinical trial versus alitretinoin... For treatment of patients with moderate-to-severe CHE which is inadequately treated by topical corticosteroids, delgocitinib cream provides both better clinical outcomes and lower costs for the healthcare payer in comparison with PUVA in the UK healthcare context."

Clinical • Cost effectiveness • HEOR • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream, alitretinoin, and psoralen with ultraviolet A (PUVA light therapy) are treatments used amongst patients with Chronic Hand Eczema (CHE) which has not adequately responded to topical corticosteroids alone. Due to limitations of available data, assumptions were required related to comparability of the IGA-CHE and PGA severity assessment tools, disease severity, treatments and outcome assessment timepoints, and the use of non-responder imputation. Notwithstanding these assumptions, amongst patients with moderate/severe CHE, treatment with delgocitinib cream is associated with both higher rates of treatment response and lower rates of discontinuation due to adverse events than either alitretinoin or PUVA light therapy."

Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

When Natural Isn't Harmless: DRESS in North America from an Asian Supplement Withdrawn Abroad (ACAAI 2025) - "HemoHIM, sold in North America, has been suspended in Hong Kong, Taiwan, and Singapore due to reports of hepatitis linked to undeclared hepatotoxic compounds, including methoxsalen and psoralen...Clinicians must obtain detailed histories explicitly addressing alternative health products and maintain a high index of suspicion for supplement-induced hypersensitivity syndromes. This case highlights a regulatory blind spot requiring greater international coordination and vigilance on supplement safety."

Eosinophilia • Hepatology • Immunology • Inflammation

Ultrastructure of human platelet concentrates after treatment with pathogen reduction technologies for prolonged storage. (PubMed, Front Med (Lausanne)) - "Immediately after splitting, single units were left untreated (CONTROL) or treated with either psoralen-UVA (INTERCEPT) or riboflavin-UVB (MIRASOL)...Platelet mitochondrial volume shrinks and canalicular system swells within the first 24 h after collection and then both remain rather constant for up to seven days with or without PRT treatment. Pathogen reduction technology - both INTERCEPT and MIRASOL - does not increase morphological platelet storage lesion."

Journal

Early nail involvement in mycosis fungoides with rapid systemic progression: rethinking the role of Ki-67: a case report. (PubMed, J Med Case Rep) - "This case suggests the potential for aggressive mycosis fungoides behavior despite indolent histopathological characteristics. Initial nail involvement might serve as a clinical marker of atypical progression. The limitations of Ki-67 alone suggest the need for comprehensive prognostic models that incorporate molecular biomarkers, such as thymocyte selection-associated high mobility group box, CD30, and T-cell receptor clonality."

IO biomarker • Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Hepatology • Lymphoma • Mycosis Fungoides • Oncology • Pain • Palliative care • Pruritus • T Cell Non-Hodgkin Lymphoma • CD4 • CD7 • CD8 • TNFRSF8

Integrated Analysis of Cross-Link-Ligation Data for the Detection of RNA 2D/3D Structures and Interactions In Vivo. (PubMed, Methods Mol Biol) - "This presents distinct challenges, as noted in recent methods, e.g., Psoralen Analysis of RNA Interactions and Structures (PARIS) and Spatial 2'-Hydroxyl Acylation Reversible Cross-linking (SHARC)...We outline the strategies used to preprocess raw data, map to a reference genome, classify reads, and assemble duplex groups. Further, we show an example of analyzing structural data for the ribosomal RNA."

Journal • Preclinical

Systematic characterization of the prototypes and metabolites of Psoraleae Fructus in mice by high-resolution liquid chromatography/ mass spectrometry. (PubMed, J Pharm Biomed Anal) - "Herein, the in vivo components in Kunming mice (e.g., the plasma, urine, and feces) associated with the water decoction of salt-processed Psoraleae Fructus (sPF), together with two major coumarins (psoralen and isopsoralen) and two flavonoids (isobavachalcone and bavachinin), were comparatively studied via ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UHPLC/QTOF-MS)...Notably, the metabolism of isopsoralen and bavachinin was reported for the first time. In conclusion, the in vivo metabolism of the sPF decoction is comprehensively investigated, which is helpful for the rational use of Psoraleae Fructus in clinic."

Journal • Preclinical

Psoralen inactivated SARS-CoV2 vaccine protects Syrian hamsters from SARS-CoV2 induced lung disease (ASTMH 2025) - "These findings suggest that PsIV-COVID-19 vaccines (Vax1- 4) effectively protect hamsters from COVID-19 challenge and Advax-2 induces less inflammation compared to alum adjuvant. Further studies are required to assess safety and efficacy of PsIV-COVID-19 vaccines."

Late-breaking abstract • Preclinical • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

MEG Reveals COVID-19 Related Reductions in Global Resting State Brain Activity in Nonhuman Primates (ASTMH 2025) - "Our findings demonstrate significant reductions in global resting state activity following viral challenge in unvaccinated subjects, with substantial preservation of neural activity in animals receiving a psoralen-inactivated SARS-CoV-2 vaccine. These results establish MEG as a powerful tool for detecting subtle yet significant changes in brain function that may be overlooked by other imaging modalities and highlight vaccination's role in mitigating neurological outcomes. This study advances our understanding of vaccine-induced neuroprotection and demonstrates MEG's value for monitoring brain function in the context of viral infections."

Clinical • CNS Disorders • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

CAR-SPLASH identifies nascent pre-mRNA structures implicated in kinetic coupling and alternative splicing. (PubMed, Proc Natl Acad Sci U S A) - "To search for RNA structures in nascent pre-mRNA, we modified Sequencing of Psoralen Crosslinked, Ligated And Selected Hybrids (SPLASH) [J...ASO disruption of these regulatory elements that we designate "RNA kinetic switches" modified AS of NISCH Exon 18, GAK Exon 7, and MEGF8 Exon 14 in a way that depends on the rate of transcription elongation. We propose that these switches mediate kinetic coupling via the effects of transcription speed on folding of nascent RNA structures that modulate AS and that many nascent RNA structures can thereby serve as targets for splice-modifying ASOs."

Journal • MEGF8

Multifunctional methacrylated gelatin-hyaluronic acid-psoralen hydrogel for bone defect repair: Synergistic anti-inflammatory, ROS-scavenging, and osteoinductive effects. (PubMed, Int J Biol Macromol) - "The incorporation of HA enhanced the hydrogel's storage modulus and swelling properties, while PSO facilitated sustained drug release and improved its bioactivity. Collectively, this study demonstrates the development and validation of a multifunctional GelMA/HA/PSO hydrogel that integrates biological (antioxidant, anti-inflammatory, osteogenic) and engineering (injectable, photo-crosslinkable) properties, with a particular emphasis on its minimally invasive potential for bone defect repair."

Journal • Infectious Disease • Mood Disorders • Oncology

Narrowband UVB and PUVA phototherapy treatment for Mycosis Fungoides: A 17 year Retrospective Cohort Study in a University Teaching Hospital, 2007-2024 (EADV 2025) - "MF is typically managed with Narrowband UVB and psoralen plus UVA (PUVA) phototherapy in the early stages, though comparative data on their efficacy remains limited... NB-UVB and PUBA are effective and well tolerated for the treatment of early-stage MF. Hypopigmented variants and early disease stage predicted better outcomes."

Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Chronic non-healing ulcer in the inguinal region: Langerhans cell histiocytosis (EADV 2025) - "Treatment options for localized disease include observation, topical nitrogen mustard, psoralen plus ultraviolet A therapy, intralesional corticosteroids or interferon, and radiotherapy. In contrast, multisystem disease typically requires systemic chemotherapy, with first-line agents including vinblastine or etoposide... This case highlights the importance of reconsidering the diagnosis in patients with chronic, non- healing ulcers that fail to respond to standard treatments. A thorough diagnostic workup —including histopathological evaluation and advanced imaging —is essential to exclude alternative etiologies, alternative causes such as inflammatory, infectious, metabolic, or neoplastic conditions. Recognizing LCH as a potential underlying cause of genital ulcers is critical for achieving a timely diagnosis and implementing appropriate therapeutic interventions."

Dermatitis • Dermatology • Diabetes • Hematological Disorders • Immunology • Langerhans Cell Histiocytosis • Metabolic Disorders • Oral Cancer • Seborrheic Dermatitis

Effective Use of Ropeginterferon alpha-2b and PUVA in CD30+ Large Cell Transformed Mycosis Fungoides Refractory to BV-CHP (EADV 2025) - "We present a case of a 54-year- old male patient with CD30-positive large cell transformation of MF who was refractory to brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone (BV-CHP), but showed significant improvement after treatment with ropeginterferon alpha-2b and psoralen plus UVA (PUVA) phototherapy. This case highlights the potential of off-label ropeginterferon alpha-2b—officially approved for polycythemia vera —in combination with PUVA as an effective and well-tolerated treatment option for advanced, treatment- refractory large cell-transformed MF (2). Despite the absence of standardized dosing guidelines, the patient demonstrated significant clinical improvement with minimal toxicity."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Leukopenia • Mycosis Fungoides • Neutropenia • Oncology • Polycythemia Vera • Thrombocytopenia • ALK • BCL2 • BCL6 • CD2 • CD4 • CD5 • CD7 • CD8 • ICOS • MME • PD-1 • TNFRSF8 • TRB

Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe Chronic Hand Eczema (EADV 2025) - P3 | "Current therapies, including topical corticosteroids, phototherapy (including psoralen ultraviolet A [PUVA]), and alitretinoin (approved for severe CHE in Europe, Canada, Israel and South Korea), may be hindered by side effects and poor patient adherence. The results of this MAIC analysis demonstrate that treatment with delgocitinib significantly improves both clinical and quality-of-life outcomes compared to PUVA plus as required TCS in severe CHE at week 12, including PGA/IGA-CHE, HECSI, and DLQI. These findings support delgocitinib as a highly efficacious and accessible alternative to PUVA ± TCS for managing severe CHE. As a topical treatment, delgocitinib also offers a more convenient alternative to PUVA based treatment, reducing the need for frequent clinic visits, alongside offering a favourable tolerability and safety profile."

Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study (EADV 2025) - "Narrow- band ultraviolet B, 308-nm excimer laser, and psoralen ultraviolet A therapy showed varying effectiveness; specifically, the excimer laser was notably effective for patients with shorter disease duration...Low-level light/laser therapy also increased hair density and diameter and exhibited potential benefits when used alongside minoxidil, but did not significantly enhance outcomes in telogen effluvium treatment. Light/laser therapy can serve as an additive treatment for cicatricial alopecia, particularly lichen planopilaris, but has limited efficacy in treating telogen effluvium. Overall, light/laser therapies exhibit a significant positive effect on increasing hair density and diameter across various alopecia types."

Clinical • Review • Alopecia • Immunology • Lichen Planus